✦ LIBER ✦

EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBITORS IN COMBINATION WITH VORAPAXAR, A PLATELET THROMBIN-RECEPTOR ANTAGONIST, AMONG PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE TRACER TRIAL

✍ Scribed by Cornel, J.H.; Tricoci, Pierluigi; Horton, john; Moliterno, David; Wallentin, Lars; Armstrong, Paul; Aylward, Philip; Huang, Zhen; Lokhnygina, Yuliya; Chen, Edmond; Leonardi, Sergio; Van de Werf, Frans; White, Harvey; Held, Claes; Strony, John; Mahaffey, Kenneth; Harrington, Robert

Book ID: 123141451
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 146 KB
Volume: 61
Category: Article
ISSN: 1558-3597
DOI: 10.1016/S0735-1097(13)60103-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The emerging role of platelet glycoprote

The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes

✍ Bolognese, Leonardo 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 366 KB

Cigarette smoking status and outcome amo

Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: Effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide

✍ David Hasdai; David R. Holmes Jr; Douglas A. Criger; Eric J. Topol; Robert M. Ca 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 615 KB

The Early Glycoprotein IIb/IIIa Inhibiti

The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

ASSOCIATION OF HUB AND SPOKE PRACTICE PA

ASSOCIATION OF HUB AND SPOKE PRACTICE PATTERNS WITH CORONARY INTERVENTION AND OUTCOMES IN NON ST ELEVATION ACUTE CORONARY SYNDROMES (NSTE ACS): INSIGHTS FROM THE EARLY GLYCOPROTEIN IIB/IIIA INHIBITION IN NSTE ACS (EARLY-ACS) TRIAL

✍ Toleva, Olga; Westerhout, Cynthia M.; Senaratne, Manohara; Bode, Christoph; Lind 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 339 KB

Efficacy and safety of enoxaparin compar

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial

✍ Harvey D. White; Neal S. Kleiman; Kenneth W. Mahaffey; Yuliya Lokhnygina; Karen 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 333 KB

Randomized evaluation of the efficacy of

Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial

✍ David H. Fitchett; Anatoly Langer; Paul W. Armstrong; Mary Tan; Aurora Mendelsoh 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB